Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
22 Fevereiro 2024 - 10:30AM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that management will present a corporate overview at The
Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer
Conference taking place in New Orleans, Louisiana on February 29 to
March 2, 2024. Management will be available for one-on-one meetings
with investors who are registered for the conference.
Presentation
Details: |
Date: |
Friday, March 1, 2024 |
Time: |
9:30 am CST / 10:30 am EST |
Webcast: |
Click HERE to view the
presentation |
Registration: |
Click HERE to register and attend
the conference |
|
|
About CAGLAThe Cancer Advocacy Group of
Louisiana, Inc. (CAGLA) is a grassroots, non-profit advocacy
organization committed to enhancing cancer care and research in
Louisiana. The NeauxCancer Conference is an annual multi-day,
multi-track CME/CE conference that attracts over 400 leaders in
oncology, including medical oncologists, cancer surgeons, radiation
oncologists, as well as advanced practice providers, medical
trainees, nurses, pharmacists, and other healthcare professionals.
The conference offers a wide variety of multi-disciplinary didactic
sessions and expert panels focused on the advanced management of
cancer patients, including the intersection of new and emerging
therapies, novel surgical approaches, radiation oncology, target
therapies immunotherapies, and the application of precision
medicine. This year’s conference features 8-10 dynamic companies in
a new investment track providing an opportunity to connect with
attendees and investment advisors in the Gulf South.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuite℠.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDx℠ risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheck℠ is the first-ever noninvasive test designed to
identify endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDx℠ test is designed to combine
microRNA and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking StatementsThis press release
may contain forward-looking statements that are made pursuant to
the safe harbor provisions of the federal securities laws,
including those relating to the timing and completion of any
products in the pipeline development and other statements that are
predictive in nature. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as “designed to,” “expect,”
“plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this press release and other
factors that may cause such differences include the satisfaction of
customary closing conditions related to the offering and the
expected timing of the closing of the offering. These and
additional risks and uncertainties are described more fully in the
company’s filings with the SEC, including those factors identified
as “risk factors” in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
Investor Relations Contact: Torsten
Hombeck, Ph.D.Chief Financial OfficerAspira Women’s
HealthInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024